Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation ...

Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing ...

Cogent Biosciences, Inc.’s COGT share price has dipped by 7.73%, which has investors questioning if this is right time to buy ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of ...

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...

The European Commission (EC) has granted marketing authorisation for AbbVie's once-a-day treatment Rinvoq (upadacitinib) 15mg ...

Tolebrutinib, an experimental drug, slowed disability progression in advanced MS by 31% in a major trial, offering hope for ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...

Results of the Phase III HERCULES trial suggest the first potential treatment option for a form of multiple sclerosis.

The off-label use of JAK inhibitors to treat JDM is common in pediatric rheumatology, with barriers to use including limited clinical trial data and insurance approval.

A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in ...